Please Enable Cookies

www.laserfocusworld.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

127.86 -3.74 (-2.84%)
Official Closing Price Updated: 7:00 PM EDT, Jul 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,326,148
Open 129.10
Bid (Size) 126.22 (1)
Ask (Size) 128.89 (8)
Prev. Close 131.60
Today's Range 126.35 - 129.98
52wk Range 77.95 - 148.15
Shares Outstanding N/A
Dividend Yield 1.38%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
Companies like Novo Nordisk and Eli Lilly might soon have a determined competitor in their hottest product category. 
Via The Motley Fool
Novo Nordisk Shares Decline Amid Competitive Pressure
Novo Nordisk A/S Common Stock (NYSE: NVO) experienced a notable decline on Thursday. This movement follows a significant announcement from competitor Viking Therapeutics Inc. (NASDAQ:VKTX). 
Via Benzinga

Performance

YTD
+25.22%
+25.22%
1 Month
-12.97%
-12.97%
3 Month
+1.65%
+1.65%
6 Month
+20.99%
+20.99%
1 Year
+61.56%
+61.56%

More News

Read More
Viking Therapeutics Stock Surges As Company Advances Weight Loss Drug To Late-Stage Trial: What Investors Need To Know
Via Benzinga
Novo Nordisk's Options Frenzy: What You Need to Know
Via Benzinga
Viking Therapeutics Unveils Monthly Weight-Loss Shot, And Rocks Eli Lilly, Novo Nordisk
Via Investor's Business Daily
Novo Nordisk Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
Via InvestorPlace
Beware, Wegovy -- Pfizer Is Working on a Competitor
Via The Motley Fool
3 Fabulous Growth Stocks to Buy and Hold Forever
Via InvestorPlace
UK's NHS Prescribes Weight-Loss Drug Wegovy Less Than Expected Due To Service Shortages
Via Benzinga
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Via Benzinga
3 Stocks to Buy if There Is No Interest Rate Cut This Year
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off
Via Benzinga
Britain's Drug Regulator Approves Novo Nordisk's Weight Loss Drug Wegovy To Cut Heart Disease Risk In Obese Patients
Via Benzinga
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
Via The Motley Fool
Why Hims & Hers Heath Shares Are Surging Today
Via Benzinga
Biden's Exit From Presidential Race 'Yet Another Curveball For Equity Investors': Analysts
Via Benzinga
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Via Benzinga
7 Sorry Biotech Stocks Set to Make Investors Sad
Via InvestorPlace
Here's My Top Growth Stock to Buy Right Now
Via The Motley Fool
3 Monster Stocks in the Making to Buy Right Now
Via The Motley Fool
Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications
Via Benzinga
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
Via Investor's Business Daily
Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval
Via Benzinga
7 A-Rated Stock Picks With Huge Upside Potential
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.